Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 13132Neoplasms 10477Carcinoma, Non-Small-Cell Lung 6870Prostatic Neoplasms 6268Colorectal Neoplasms 5945Lung Neoplasms 5102Multiple Myeloma 3576Pancreatic Neoplasms 3561Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3507Carcinoma, Hepatocellular 3271Ovarian Neoplasms 3168Melanoma 3139Stomach Neoplasms 3056Lymphoma 2982Head and Neck Neoplasms 2603Recurrence 2556Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2327Brain Neoplasms 2310Lymphoma, Non-Hodgkin 2268Rectal Neoplasms 2191Uterine Cervical Neoplasms 2191Glioblastoma 2014Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1847Esophageal Neoplasms 1800

Interventions

ON 01910 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Epidermolysis Bullosa Dystrophica × Clear all
NCT03786237 2026-02-24

Rigosertib for RDEB-SCC

Salzburger Landeskliniken

Phase 1/2 Completed
2 enrolled

Carcinoma, Squamous Cell, Epidermolysis Bullosa Dystrophica

NCT05843994 2026-02-03

Artificial Intelligence Patient App for RDEB SCCs

Northwestern University

Active not recruiting
20 enrolled
Dermatologic

Congenital Abnormalities, Carcinoma, Squamous Cell, Epidermolysis Bullosa, Skin Abnormalities, Skin Diseases, Skin Diseases, Vesiculobullous, Skin Diseases, Genetic, Skin Neoplasms, Epidermolysis Bullosa Dystrophica, Genetic Diseases, Inborn

NCT06423573 2025-09-19

FOSteR

Amryt Pharma

Recruiting
580 enrolled

Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa, Junctional

Data powered by HemOnc (CC BY 4.0) Colophon âš¡